NAT6 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q93015 |
Other Accession | NP_036323.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 31445 Da |
Antigen Region | 150-179 aa |
Gene ID | 24142 |
---|---|
Other Names | N-acetyltransferase 6, 231-, Protein fusion-2, Protein fus-2, NAT6, FUS2 |
Target/Specificity | This NAT6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 150-179 amino acids from the Central region of human NAT6. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | NAT6 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | NAA80 {ECO:0000303|PubMed:29581253, ECO:0000312|HGNC:HGNC:30252} |
---|---|
Function | N-alpha-acetyltransferase that specifically mediates the acetylation of the acidic amino terminus of processed forms of beta- and gamma-actin (ACTB and ACTG, respectively) (PubMed:30028079, PubMed:29581253). N-terminal acetylation of processed beta- and gamma- actin regulates actin filament depolymerization and elongation (PubMed:29581253). In vivo, preferentially displays N-terminal acetyltransferase activity towards acid N-terminal sequences starting with Asp-Asp-Asp and Glu-Glu-Glu (PubMed:30028079, PubMed:29581253). In vitro, shows high activity towards Met-Asp-Glu-Leu and Met-Asp-Asp-Asp (PubMed:10644992, PubMed:29581307). May act as a tumor suppressor (PubMed:10644992). |
Cellular Location | Cytoplasm, cytosol |
Tissue Location | Strongly expressed in heart and skeletal muscle, followed by brain and pancreas, with weak expression in kidney, liver, and lung and no expression in placenta. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NAT6 seems to be involved in N-acetylation. Acts on peptides with a N-terminal Met followed by Asp/Glu/Asn. May act as a tumor suppressor.
References
Young, R.P., et al. Postgrad Med J 85(1008):515-524(2009)
Muzny, D.M., et al. Nature 440(7088):1194-1198(2006)
Duh, F.M., et al. Mol. Cell. Probes 18(1):39-44(2004)
Shuttleworth, T.L., et al. J. Biol. Chem. 277(25):23008-23018(2002)
Lerman, M.I., et al. Cancer Res. 60(21):6116-6133(2000)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.